Clinical Trials Results - National Cancer Institute

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -8 of 8 Show results per page	View Search Criteria \| Help With Results

Last Modified: 11/22/2005


1.		Phase III Randomized Study of Ovarian Suppression in Premenopausal Women Receiving Adjuvant Chemotherapy for Poor-Prognosis Nonmetastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				premenopausal								FRE-FNCLCC-9456 NCI-F94-0023

Last Modified: 7/6/2007 First Published: 7/1/1997


2.		Phase III Study of Long Term Adjuvant Hormonal Treatment With LHRH Analogue (Triptorelin) Versus No Further Treatment in Patients With Locally Advanced Prostatic Carcinoma Treated by External Irradiation and a Six Month Combined Androgen Blockage

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				Any age				Other				EORTC-22961 EORTC-GU-22961, NCT00003026

Last Modified: 5/31/2007 First Published: 3/1/1999


3.		Phase III Randomized Neoadjuvant Study of Short Versus Protracted Hormonal Therapy Prior to Radiotherapy in Patients With Stage I-IV Localized Prostate Cancer (Summary Last Modified 06/2002)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Other				ICORG-97-01 EU-98060, NCT00003734

Last Modified: 10/23/2008 First Published: 7/26/2003


4.		Phase III Randomized Study of Ovarian-Function Suppression and Tamoxifen or Exemestane With Versus Without Adjuvant Chemotherapy in Premenopausal Women With Endocrine-Responsive Resected Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				Premenopausal				NCI				IBCSG-26-02 BIG-4-02, NABCI-IBCSG-26-02, EU-20401, NCT00066807, EUDRACT-2005-002626-59

Last Modified: 4/16/2008 First Published: 3/27/2006


5.		Phase III Randomized Study of Triptorelin for Prevention of Chemotherapy-Induced Menopause in Premenopausal Women Undergoing Adjuvant Chemotherapy for Previously Resected Stage I-III Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Biomarker/Laboratory analysis, Supportive care, Treatment				Completed				18 to 45				Other				GIM-6 GIM-PROMISE, EU-20606, GIM-5104, NCT00311636

Last Modified: 6/1/1988


6.		Phase II Study of D-Trp-6-LHRH (Decapeptyl) in Patients with Advanced Ovarian Carcinoma (Summary Last Modified 06/88)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over								EORTC-55876

Last Modified: 6/6/2008 First Published: 8/24/2004


7.		Phase II Randomized Study of Triptorelin for Preserving Ovarian Function in Premenopausal Women With Early-Stage Operable Breast Cancer Undergoing Adjuvant or Neoadjuvant Systemic Chemotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Supportive care				Completed				Under 45				NCI				MCC-0203 NCI-7031, NCT00090844, 7031, HLMCC 0203


8.		Study to Assess the Non-Inferiority of Pamorelin® 11,25mg SC Injected Versus Pamorelin® 11,25mg IM Injected in Patients Suffering From Advanced Prostate Cancer (PAMOJECT)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Temporarily closed				18 and over				Pharmaceutical / Industry				I-48-52014-142 NCT00444639

Select All on One Page